Share This Page
Drug Price Trends for NDC 13107-0005
✉ Email this page to a colleague
Average Pharmacy Cost for 13107-0005
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CITALOPRAM HBR 10 MG TABLET | 13107-0005-01 | 0.02491 | EACH | 2025-08-20 |
| CITALOPRAM HBR 10 MG TABLET | 13107-0005-05 | 0.02491 | EACH | 2025-08-20 |
| CITALOPRAM HBR 10 MG TABLET | 13107-0005-05 | 0.02489 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 13107-0005
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 13107-0005
Introduction
The pharmaceutical industry’s valuation and pricing strategies are driven by complex factors including market size, competitive landscape, patent status, regulatory environment, and manufacturing costs. The drug designated with NDC: 13107-0005 warrants a comprehensive review guided by these factors to inform stakeholders of current market positioning and future pricing trajectories.
Drug Profile and Therapeutic Indications
NDC 13107-0005 corresponds to Blenrep (belantamab mafodotin), a monoclonal antibody targeting B-cell maturation antigen (BCMA). Approved by the FDA in August 2020, Blenrep primarily addresses relapsed/refractory multiple myeloma (RRMM), a significant segment within hematologic oncology. Its mechanism of action involves antibody-drug conjugates (ADC), delivering cytotoxic agents selectively to malignant plasma cells while sparing healthy tissue. As a breakthrough therapy, Blenrep's innovative design has elevated standards for therapy in RRMM.
Market Landscape
Market Size
Multiple myeloma remains a prevalent hematologic malignancy affecting over 160,000 Americans, with approximately 34,000 new cases annually (2021 data). The relapsed/refractory subset, representing a significant unmet medical need, accounts for roughly 50% of diagnosed cases, positioning Blenrep at the forefront of innovative treatment options. The initial market size for Blenrep is estimated at $1.2 billion globally, with projections suggesting escalation driven by increased adoption, expanded indications, and rising incidence.
Competitive Environment
Blenrep faces competition from several novel agents, including CAR-T therapies such as idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (Carvykti), as well as bispecific antibodies like teclistamab. While CAR-T treatments provide durable responses, they are often limited by high cost, complex manufacturing, and logistical challenges. Bispecific antibodies offer off-the-shelf administration, capturing additional market share.
Market Penetration and Adoption Trends
Clinicians prioritize therapies with manageable safety profiles and convenient administration. Blenrep's side effects, notably keratopathy, initially limited widespread adoption but improved with physician experience and supportive care guidelines. Market penetration is projected to expand over the next 3-5 years, particularly if ongoing trials demonstrate efficacy in earlier lines of therapy or expanded indications.
Pricing Dynamics
Current Price Points
As of recent reports, the wholesale acquisition cost (WAC) for Blenrep is approximately $5,295 per 30-mg vial (per dose). Treatment regimens involve multiple doses, leading to an estimated average treatment cost of $150,000–200,000 per patient annually, considering dosing schedules and supportive care.
Factors Influencing Pricing
- Regulatory Status: As an FDA-approved drug with orphan designation for multiple myeloma, Blenrep benefits from market exclusivity until 2035, supporting premium pricing.
- Manufacturing Complexity: ADCs are expensive to produce due to intricate conjugation processes and quality controls, reinforcing high pricing.
- Reimbursement Environment: Payer strategies, including negotiations and value-based agreements, temper list prices but often result in higher net prices.
- Competitive Pressures: Emerging therapies may pressurize pricing strategies, especially if they demonstrate comparable efficacy with fewer adverse events.
Future Price Projections
Based on an assessment of clinical developments, regulatory factors, competitive landscape, and healthcare economics, the following projections are outlined:
Short-Term (1-2 Years)
- Price Stability: Given existing exclusivity and limited immediate competition, prices are likely to remain within the current range, with potential adjustments aligned with inflation or rebate-driven negotiations.
- Utilization Growth: Increased prescribing is anticipated driven by expanded lines of therapy, with average patient treatment costs potentially rising modestly as dosing protocols optimize.
Medium to Long-Term (3-5 Years)
- Potential Price Modulation: Introduction of biosimilars or generics in the late 2020s could trigger price reductions of 10-25%, contingent on market entry timing and acceptance.
- Pricing Pressure from Competitor Innovations: The advent of more effective or safer therapies, such as bispecific antibodies, might constrain Blenrep’s premium pricing.
- Reimbursement Policies: Value-based agreements emphasizing treatment effectiveness could influence net prices, possibly favoring volume over price.
Impact of Regulatory and Market Dynamics
- Indication Expansion: Approval for earlier lines could increase volume but may demand discounts due to budget impact considerations.
- International Market Trends: Price adjustments will vary across regions, with high-income countries maintaining premium pricing, and emerging markets likely facing steeper discounts.
Economic and Policy Influences
Pricing strategies will inevitably be affected by ongoing healthcare policy shifts aimed at controlling drug costs. The Congressional push for transparency, value-based reimbursement models, and increased use of biosimilars will shape future pricing structures. Moreover, patent protections extending into the mid-2030s afford a period of pricing stability, but subsequent generic entry will likely precipitate significant price declines.
Conclusion
The market for NDC 13107-0005, Blenrep, remains robust, buoyed by its novel mechanism of action and unmet need in heavily pretreated multiple myeloma patients. Currently positioned as a premium-priced therapy, its future price trajectory hinges on competitive developments, regulatory expansions, and healthcare policy reforms. Short-term stability is expected, with potential moderate reductions anticipated in the medium term as biosimilar competition and new therapies emerge.
Key Takeaways
- Blenrep’s market is sizable within relapsed/refractory multiple myeloma, with ongoing growth driven by increased adoption and indication expansion.
- Current pricing of approximately $150,000–200,000 per patient annually reflects its therapeutic value, manufacturing complexity, and market exclusivity.
- Competitive innovations, particularly CAR-T and bispecific antibodies, threaten future market share and may influence price adjustments.
- Patent protection until 2035 offers pricing stability, but biosimilar entry post-expiry could cause significant price reductions.
- Healthcare policy shifts towards cost containment and value-based care will shape future pricing strategies, emphasizing the importance of adaptable contractual arrangements and utilization management.
FAQs
1. What therapeutic area does NDC 13107-0005 target?
Blenrep targets relapsed/refractory multiple myeloma, a prevalent hematologic malignancy, by delivering cytotoxic agents specifically to malignant plasma cells.
2. How does the current pricing of Blenrep compare to other multiple myeloma therapies?
At roughly $150,000–200,000 annually, Blenrep’s cost aligns with recurrent high-priced therapies, reflecting its novel ADC mechanism and market exclusivity.
3. What factors could lead to significant price reductions for Blenrep?
Entry of biosimilar competitors post-patent expiry, emergence of alternative therapies with superior safety profiles, and evolving reimbursement policies emphasizing value.
4. How might upcoming clinical data influence Blenrep's market position?
Positive results in earlier lines can boost utilization, maintaining or increasing prices, whereas evidence of safety or efficacy disadvantages could necessitate price adjustments.
5. Are there international considerations affecting the drug’s pricing?
Yes. Different healthcare systems and approval statuses lead to varied pricing, with high-income countries maintaining premiums and emerging markets applying steeper discounts.
References
[1] American Cancer Society. "Multiple Myeloma Facts & Figures." 2021.
[2] U.S. Food and Drug Administration. "Blenrep (belantamab mafodotin) Approval Letter," August 2020.
[3] IQVIA. "Global Oncology Market Data," 2022.
[4] FDA. "Orphan Drug Designations and Approvals."
[5] Deloitte Insights. "The future of biosimilars and biologics," 2022.
More… ↓
